Chief Medical Officer

Hlx is partnering with a clinical-stage biotechnology company developing innovative therapies for rare renal diseases. With a lead programme in Phase II, the company is entering a critical stage of development and value creation.

We are seeking a hands‑on Chief Medical Officer to work closely with the CEO as a true strategic partner. This role combines leadership and execution, with a strong emphasis on external engagement across investors, Key Opinion Leaders, and partners. The successful candidate will play a central role in shaping both the clinical strategy and the broader company narrative.

Responsibilities

• Lead the clinical development strategy and execution for the company’s Phase II programme and pipeline
• Provide hands‑on oversight of trial design, execution, and data interpretation in a lean operating model
• Act as a key partner to the CEO on company strategy, prioritisation, and growth initiatives
• Play a central role in investor engagement, including fundraising, diligence, and presenting to investors and the Board
• Build and maintain strong relationships with global KOLs, investigators, and patient advocacy groups
• Represent the company at scientific congresses and industry events
• Lead regulatory interactions (FDA, EMA) and overall development pathway
• Integrate translational insights, including biomarkers and patient stratification strategies
• Support the build‑out of the clinical and medical function as the company scales

Qualifications

• MD or MD/PhD; nephrology expertise strongly preferred – ideally nephrologist or cardio/metabolic focused
• Proven track record leading clinical development programmes through Phase II
• Demonstrated experience working closely with investors and KOLs in an externally facing capacity
• Prior experience in a small or mid‑sized biotech environment preferred
• Strong strategic and operational capabilities; able to operate in a hands‑on, resource‑conscious setting
• Excellent communication skills with the ability to translate complex science for diverse audiences
• Credible external presence with regulators, investigators, and the investment community

Next Steps

For a confidential discussion or to express interest, please get in touch directly. We are actively engaging with a select group of candidates and welcome early conversations.